【レポートの概要（一部）】
1. Report Overview
1.1 Breast Cancer Drugs Overview
1.2 Why you Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Breast Cancer and its Treatment
2.1 What is Breast Cancer?
2.2 The Second Most Common Cancer in the World
2.3 Normal Structure of the Human Breast
2.4 Classifying the Different Types of Breast Cancer
2.4.1 Pathology
2.4.2 Molecular Subtype
2.4.3 Stages
2.4.4 Grades
2.5 Treatment Protocols
2.5.1 Treatment Options for Localised Disease
2.5.1.1 The Different Types of Therapy for Localised Breast Cancer
2.5.1.2 Stage 0 – Lobular Carcinoma in Situ (LCIS) and Ductal Carcinoma in Situ (DCIS)
2.5.1.3 Adjuvant Chemotherapy and Adjuvant Hormonal Therapy Treatment Options for Stage 1-3 Localised Disease
2.5.2 Treatment Options for Recurrent or Metastatic Disease
3. Leading Breast Cancer Drugs
3.1 Herceptin (trastuzumab) by Roche: The Leading Breast Cancer Drug
3.1.1 Approved Indications: Breast Cancer is the Main Indication
3.1.2 Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
3.1.3 Total Herceptin Revenues 2010-2015
3.1.4 The Threat of Biosimilars
3.1.4.1 Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
3.1.4.2 Herzuma (Celltrion)
3.1.4.3 Total Biosimilar Trastuzumab Revenue Forecast, for all Indications, 2016-2026
3.1.5 Herceptin for Breast Cancer Revenue Forecast 2016-2026
3.2 Perjeta (pertuzumab) by Roche
3.2.1 Is a Recent Addition to the Market, Approved for Different Stages of Breast Cancer
3.2.2 Positive Results from Different Clinical Trials
3.2.3 Total Perjeta Revenues 2012-2015
3.2.4 Perjeta for Breast Cancer Revenue Forecast 2016-2026
3.3 Afinitor (everolimus) by Novartis
3.3.1 Multiple Approved Indications but Breast Cancer Leads
3.3.2 No Extension to HER2 Positive Breast Cancer, as Afinitor Fails to Meet Primary Objective in Phase 3 Trial
3.3.3 NICE Rejects Afinitor on Cost Basis, although Drug Remains on the Cancer Drugs Fund, Despite Rumours it Would be Removed
3.3.4 Total Afinitor Revenues 2010-2015
3.3.5 Afinitor for Breast Cancer Revenue Forecast 2016-2026
3.4 Faslodex (fulvestrant) by AstraZeneca
3.4.1 Approved for Breast Cancer all the Way Back in 2002, Higher Dose Approved in 2010
3.4.2 Patent Dispute with Mylan
3.4.3 Total Faslodex Revenues 2010-2015
3.4.4 Faslodex for Breast Cancer Revenue Forecast 2016-2026
3.5 Ibrance (palbociclib) by Pfizer
3.5.1 Accelerated Approval on the Back of Promising Data
3.5.2 Has Already Been Used to Treat Over 15,000 Patients, MAA Filed in Europe
3.5.3 Total Ibrance Revenues Q1-Q4 2015
3.5.4 Ibrance for Breast Cancer Revenue Forecast 2016-2026
3.6 Avastin (bevacizumab) by Roche
3.6.1 Multiple Approved Indications, Still Approved for Breast Cancer in Major Markets, Except for the US
3.6.1.1 Why was the FDA-Breast Cancer Label Withdrawn?
3.6.2 Total Avastin Revenues 2010-2015
3.6.3 Avastin for Breast Cancer Revenue Forecast 2016-2026
3.6.4 No Biosimilars Approved yet, but Multiple Candidates in Clinical Trials
3.6.5 Total Biosimilar Bevacizumab Revenue Forecast, for all Indications, 2016-2026
3.7 Kadcyla (ado-trastuzumab emtansine) by Roche
3.7.1 The First Antibody-Drug Conjugate to be Approved for Breast Cancer
3.7.2 Mixed Results from Different Clinical Trials
3.7.3 Total Kadcyla Revenues 2013-2015
3.7.4 Kadcyla for Breast Cancer Revenue Forecast 2016-2026
3.8 Femara (letrozole) by Novartis
3.8.1 Hormone Therapy for Early Breast Cancer
3.8.2 Total Femara Revenues 2010-2025
3.8.3 Femara for Breast Cancer Revenue Forecast 2016-2026
3.9 Abraxane (paclitaxel Protein-Bound) by Celgene
3.9.1 Breast Cancer was the first of its Approved Indications
3.9.2 Total Abraxane Revenues 2010-2015
3.9.3 Abraxane for Breast Cancer Revenue Forecast 2016-2026
4. Breast Cancer Drugs R&D Pipeline 2016-2026
4.1 Roche: Not Content with Dominating Current Market, Already Grooming Future Leaders
4.1.1 Taselisib (GDC-0032 / RG7604)
4.1.1.1 Positive Results from Phase 1 Trial
4.1.2 Atezolizumab (MPDL3280A / RG7446)
4.1.2.1 Early Results in Triple-Negative Breast Cancer
4.1.3 Investigating Kadcyla and Perjeta in Wider Breast Cancer Indications
4.2 Novartis
4.2.1 Buparlisib (BKM120)
4.2.1.1 Early-Results for Buparlisib in Combination with Olaparib
4.2.2 Alpelisib (BYL719)
4.2.3 Ribociclib (LEE011)
4.2.3.1 Phase 1b Results in Combination with Femara
4.3 AstraZeneca
4.3.1 AZD5363
4.3.1.1 Well Tolerated and Yielding Partial Response in Early Results from 2013
4.3.2 MEDI-573 (In Partnership with MedImmune)
4.4 Abemaciclib (LY2835219) by Eli Lilly
4.4.1 Coveted Breakthrough Therapy Designation from the FDA
4.5 Veliparib (ABT-888) by AbbVie
4.6 Ganetespib by Synta Pharmaceuticals
4.7 Entinostat by Syndax Pharmaceuticals
4.7.1 Syndax Collaborating with Merck and Roche, Breakthrough Therapy Designation
4.8 Lucitanib by Clovis Oncology
4.9 Glembatumumab vedotin (CDX-011) by Celldex Therapeutics
4.9.1 Results from EMERGE Study
4.10 MM-302 by Merrimack
4.10.1 Phase 1 Results Released April 2015
4.11 Neratinib (PB272) by Puma Biotechnology
4.12 ENMD-2076 by CASI Pharmaceuticals
4.13 Margetuximab by MacroGenics
5. Global Breast Cancer Drugs Market 2016-2026
5.1 The Global Breast Cancer Drugs Market Forecast 2016-2026
5.2 What Factors will Drive Growth in the Global Breast Cancer Drugs Market?
5.3 Increasing Rate of Breast Cancer
5.3.1 What Factors are Contributing to this Increase?
5.4 Dynamic and Lucrative Sector with Strong R&D Pipeline
5.5 The Use of Combination Therapies Brings Various Benefits to Both Patients and Companies
5.6 What Factors will Restrain Growth in the Breast Cancer Drugs Market?
5.7 Patent Expiries for Key Drugs Will Open up Market to Generic and Biosimilar Competition
5.8 Declining Healthcare Budgets Lead to Cost Pressures
5.9 New Therapies that Only Offer Modest Benefits over Existing Treatments, and Intense Competition
5.10 SWOT Analysis of the Global Breast Cancer Drugs Market
6. Leading Therapeutic Segments and National Markets within the Global Breast Cancer Drugs Market
6.1 The Main Therapeutic Segments within the Breast Cancer Drugs Market, Forecast 2016-2026
6.1.1 Therapeutic Composition of the Market in 2015, 2020 and 2026
6.1.2 Monoclonal Antibodies (mAbs) Segment Forecast 2016-2026
6.1.3 Chemotherapy and Hormone Therapy Segment
6.1.4 Kinase Inhibitor Segment Forecast 2016-2026
6.1.5 ‘Other’ Segment Forecast 2016-2026
6.2 Leading National Markets for Breast Cancer Drugs
6.2.1 Leading Regional Markets for Breast Cancer, Forecast 2016-2026
6.2.2 Regional Composition of the Market in 2015, 2020 and 2026
6.2.3 US Breast Cancer Drugs Market 2016-2026
6.2.3.1 The Dominant National Market, and will Remain so Throughout the Forecast Period, Although is Undergoing Some Changes
6.2.3.2 US Breast Cancer Drugs Market Forecast 2016-2026
6.2.4 EU5 Breast Cancer Drugs Market 2016-2026
6.2.4.1 German Breast Cancer Drugs Market: The Leading EU Market, Undergoing Reforms
6.2.4.2 German Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.3 French Breast Cancer Drugs Market: Some Reduction in Healthcare Spending, but National Healthcare System Remains Strong
6.2.4.4 French Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.5 Italian Breast Cancer Drugs Market: Facing Challenges
6.2.4.6 Italian Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.7 UK Breast Cancer Drugs Market: Pricing is a Contentious Issue
6.2.4.8 UK Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.9 Spanish Breast Cancer Drugs Market
6.2.4.10 Spanish Breast Cancer Drugs Market Forecast 2016-2026
6.2.5 Japanese Breast Cancer Drugs Market
6.2.5.1 Rapidly Ageing Population will Boost the Market, but will a Successful Generic Market be Established?
6.2.5.2 Japanese Breast Cancer Drugs Market Forecast 2016-2026
6.2.6 BRIC Breast Cancer Drugs Market
6.2.6.1 Chinese Breast Cancer Drugs Market: Nation to Become one of the Major Global Players due to Rapid Growth
6.2.6.2 Chinese Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.3 Brazilian Breast Cancer Drugs Market: Healthcare in the Country is Taking Great Strides Forward
6.2.6.4 Brazilian Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.5 Russian Breast Cancer Drugs Market: Punches Below its Weight
6.2.6.6 Russian Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.7 Indian Breast Cancer Drugs Market: Generics are King
6.2.6.8 Indian Breast Cancer Drugs Market Forecast 2016-2026
7. Research Interviews
7.1 Interview with Dr Ken Ren, CEO of CASI Pharmaceuticals
7.1.1 On ENMD-2076 for Triple Negative Breast Cancer
7.1.2 Status of the Chinese Oncology Market
7.1.3 On the Properties that will Allow CASI to compete Against Giants in the Market, Such as Roche
7.1.4 On Drivers and Restraints for the Market
7.1.5 On the Challenges of Developing a Pipeline Product for the Breast Cancer Market, and Ways of Overcoming Them
7.2 Interview with MacroGenics
7.2.1 On Margetuximab for Metastatic Breast Cancer
7.2.2 On Where Margetuximab would fit into the Competitive HER2 Space
7.2.3 On the Challenges of Developing a Pipeline Product
8. Conclusions from Our Research and Analysis
8.1 How will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How will the Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks
【レポート販売概要】
■ タイトル：乳がん治療薬の世界市場：モノクローナル抗体、ホルモン、化学療法、キナーゼ阻害剤、その他■ 英文：Breast Cancer Drugs Market 2016-2026 : Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals
■ 発行日：2016年3月
■ 調査会社：visiongain
■ 商品コード：VGAIN6041534
■ 調査対象地域：グローバル
- 世界の先進CO2センサー市場2015The Global Advanced CO2 Sensors Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Advanced CO2 Sensors industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Advanced CO2 Sensors market analysis is provided for the international markets including develop …
- Miller Energy, Inc.社の石油・ガス開発・生産動向及びコスト分析（2013年）Miller Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - 2013 Summary Miller Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key …
- 再生カーボンブラック（RCB）の世界市場展望2017-2026According to Stratistics MRC, the Global Recovered Carbon Black Market is accounted for $40.34 million in 2017 and is expected to reach $1,815.26 million by 2026 growing at a CAGR of 52.6% during the forecast period. Some of the key factors influencing the market growth include abundant availability of ELTS, the raw material for rCB production, growing environmental concern towards low carbon foot …
- Hyperuricemia：グローバル臨床試験レビューH2, 2013Hyperuricemia Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Hyperuricemia Global Clinical Trials Review, H2, 2013" provides data on the Hyperuricemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperuricemia. It includes an overview of the trial numbers and their recruitment status as per the …
- Hadoopの世界市場2015-2022According to Stratistics MRC, the global hadoop market is expected to grow at a CAGR of 53.7% over the forecast period 2015 to 2022. Increasing investments in data management, rising amount of structured and unstructured data, hasty growth in consumer data and rapidly increasing demand for big data analytics are the factors influencing the market growth. Furthermore, advancements in technology, in …
- 世界のハロゲンライト市場：Global Automotive Halogen Lighting Market 2014-2018TechNavio's analysts forecast the Global Automotive Halogen Lighting market to grow at a CAGR of 1.24 percent over the period 2013-2018. One of the key factors contributing to this market growth is the easy accessibility across all geographies. The Global Automotive Halogen Lighting market has also been witnessing the continuing adoption of halogen lamps in low-cost vehicles. However, the excess g …
- 世界のインフルエンザ検査市場The report presents a detailed analysis of the Influenza diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Influenza definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Com …
- エネルギー改修システムの世界市場：住宅エネルギー改修、商用ビル/公共ビルエネルギー改修About Energy Retrofit Systems Energy retrofits refer to the revamping of existing buildings to reduce their overall energy consumption and GHG emissions. With rising costs of energy and growing GHG emissions, the owners of both residential, commercial, and public buildings are taking measures to improve the energy efficiency of their buildings. In EU countries, the local governments have mandated …
- 世界のスマートサーモスタット市場（2014-2018）TechNavio’s analysts forecast the Global Smart Thermostats market will grow at a CAGR of 52.72 percent over the period 2013-2018. One of the key factors contributing to this market growth is the convenience of customers being able to control thermostats remotely. The Global Smart Thermostats market has also been witnessing an increase in the number of home energy management system companies. Howev …
- 液体・ガス濾過装置/精製装置市場（～2019）：世界市場The expansion of the global liquid and gas filtering and purifying equipment industry is forecast to reach 4.0% p.a. in the coming years. Between 2008 and 2014 the market increased with an average annual growth of 7.2%. Currently, water filtering and purifying equipment accounts for 12.1% of the global demand while the remaining market share is divided between other beverage filtering and purifyin …
- キッチンタオルの世界市場2015-2019About kitchen towels Kitchen towels are home care products that are produced from paper, cotton, or fiber. The intensification of aesthetic features and quality of materials have led to a quest for home care products, including kitchen towels, dish cloths, and tea towels. The global kitchen towel market is expected to show a steady growth during 2014-2019. The Americas dominated the market in 2014 …
- 測量機器の世界市場2017-2021About Surveying Equipment Surveying is the technology of detecting the relative position of a point that is at the surface of the earth (or above or below the surface of the earth). There are different types of surveying techniques like geodetic surveys, cadastral surveys, engineering surveys, aerial surveys, mining surveys, and hydrographic surveys. Technavio’s analysts forecast the global survey …
- 世界の紫外線硬化樹脂市場2015The Global UV Curable Resins Industry 2015 Market Research Report is a professional and in-depth study on the current state of the UV Curable Resins industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The UV Curable Resins market analysis is provided for the international markets including development tren …
- 空気圧装置の世界市場：空気圧シリンダ、空気圧弁、空気圧エンジン・モータAbout Pneumatic Equipment Pneumatic equipment uses compressed air to produce mechanical motion. The equipment is majorly used in unpredictable environments in which hydraulic or electric tools cannot be used such as in refineries, which involve the presence of flammable liquids and gases. Pneumatic equipment is increasingly being adopted by end-users for industrial applications as it is driven by …
- 無給油コンプレッサーの世界市場分析：製品別（固定式、ポータブル）、技術別（往復、ロータリー、遠心）、用途別（製造業、石油・ガス、エネルギー、F＆B、ヘルスケア、半導体・電子）、セグメント予測、2014-2024The global oil free air compressors market is expected to reach USD 15.2 billion by 2025, according to a new report by Grand View Research, Inc. Air compressors are heavily used in manufacturing applications, for instance, oil-free air is directly used in various locations as a power source for manufacturing machines. A strong demand from the food & beverage sector, owing to the mandatory health & …
